Amgen Inc. (AMGN)
232.65 +5.13 (2.25%)
Pre-market: 4:11AM EST
| Previous close | 229.99 |
| Open | 229.99 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's range | 226.90 - 230.50 |
| 52-week range | 177.05 - 276.69 |
| Volume | 2,395,212 |
| Avg. volume | 2,497,565 |
| Market cap | 131.408B |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | 18.48 |
| EPS (TTM) | 12.31 |
| Earnings date | 28 Apr 2021 - 03 May 2021 |
| Forward dividend & yield | 7.04 (3.06%) |
| Ex-dividend date | 11 Feb 2021 |
| 1y target est | 254.24 |
- PR Newswire
Amgen To Present At The Cowen 41st Annual Healthcare Conference
Amgen (NASDAQ:AMGN) will present at the Cowen 41st Annual Virtual Healthcare Conference at 12:50 p.m. ET on Thursday, March 4, 2021. Murdo Gordon, executive vice president of Global Commercial Operations and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
- Motley Fool
Why Turning Point Is Turning Heads
This oncology biotech is up over 450% since its April 2019 IPO. Are there still gains to come, or should investors turn away?
- PR Newswire
Amgen To Webcast Investor Meeting At AAAAI Virtual Annual Meeting
Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting on Friday, Feb. 26, at 1:00 p.m. ET. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with clinical trial investigators, will discuss the results of the tezepelumab Phase 3 NAVIGATOR study in patients with severe asthma.
